<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Elapegademase: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Elapegademase: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Elapegademase: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="119257" href="/d/html/119257.html" rel="external">see "Elapegademase: Drug information"</a> and <a class="drug drug_patient" data-topicid="119321" href="/d/html/119321.html" rel="external">see "Elapegademase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52120396"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Revcovi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F51982215"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme</span></li></ul></div>
<div class="block dop drugH1Div" id="F52093540"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1aca6954-55dc-4f49-a7e5-fe9b67a9cb61">Adenosine deaminase severe combined immune deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adenosine deaminase severe combined immune deficiency (ADA-SCID): Note:</b> Treatment should be individualized and based on laboratory values (eg, adenosine deaminase [ADA] activity, deoxyadenosine nucleotides [dAXP] concentrations) and clinical response; the youngest patient treated in a study was 3 months of age.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pegademase bovine (Adagen)-naive patients:</i>
<b>Note:</b> Dose should be based on actual body weight or ideal body weight (whichever is greater):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IM: 0.4 mg/kg/<b>week</b> divided into 2 weekly doses (0.2 mg/kg/dose twice weekly); continue for a minimum of 12 to 24 weeks until immune reconstitution is achieved. Following achievement of immune reconstitution, adjust dose down to maintain trough ADA activity &gt;30 mmol/hour/L, trough dAXP concentration &lt;0.02 mmol/L, and/or to maintain immune reconstitution based on clinical assessment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from pegademase bovine (Adagen) to elapegademase (Revcovi):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">Previous pegademase bovine (Adagen) dose unknown or ≤30 units/kg: IM: 0.2 mg/kg/<b>week</b> of elapegademase administered once weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Previous pegademase bovine (Adagen) dose &gt;30 units/kg: Calculate weekly elapegademase dose based on the following equation; may administer calculated dose once weekly or may divide into multiple doses in a week: IM:</p>
<p style="text-indent:-2em;margin-left:12em;">Elapegademase dose (mg/kg/<b>week</b>) = Pegademase bovine (Adagen) dose (units/kg/<b>week</b>)/150</p>
<p style="text-indent:-2em;margin-left:8em;">Subsequent elapegademase doses: IM: Increase dose by increments of 0.033 mg/kg/<b>week</b> if trough ADA activity &lt;30 mmol/hour/L, trough dAXP level &gt;0.02 mmol/L, and/or if immune reconstitution is inadequate based on clinical assessment.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51999099"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51999100"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F52093539"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="119257" href="/d/html/119257.html" rel="external">see "Elapegademase: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1aca6954-55dc-4f49-a7e5-fe9b67a9cb61">Adenosine deaminase severe combined immune deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adenosine deaminase severe combined immune deficiency:</b>
<b>IM: Note:</b> Optimal long-term dose and administration schedule should be individualized based on laboratory values (eg, adenosine deaminase [ADA] activity, trough deoxyadenosine nucleotides [dAXP] concentration) and clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Pegademase bovine naive patients:</b></i>Initial: 0.2 mg/kg (based on ideal body weight or actual body weight, whichever is greater) twice weekly for a minimum of 12 to 24 weeks. After immune reconstitution is achieved, adjust dose to maintain trough ADA activity &gt;30 mmol/hour/L, trough dAXP &lt;0.02 mmol/L, and/or to maintain immune reconstitution based on clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients transitioning from pegademase bovine:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Pegademase bovine weekly dose unknown or dose ≤30 units/kg: Initial: Minimum of 0.2 mg/kg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Pegademase bovine weekly dose &gt;30 units/kg: Initial: Calculate dose based on following formula:</p>
<p style="text-indent:-2em;margin-left:8em;">Elapegademase dose (mg/kg) = (pegademase bovine dose [units/kg])/150</p>
<p style="text-indent:-2em;margin-left:6em;">Increase dose by increments of 0.033 mg/kg once weekly if ADA trough activity &lt;30 mmol/hour/L, trough dAXP &gt;0.02 mmol/L, and/or immune reconstitution is inadequate based on clinical response; may divide total weekly dose into multiple administrations during a week.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F52093541"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F52093542"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F51999090"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormal gait, fatigue, migraine, seizures</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Facial swelling, fungal skin infection, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental caries, diarrhea, gastrointestinal infection, hematochezia, nausea, oral candidiasis, tooth loss (extraction), upper abdominal pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy, neutropenia, pulmonary hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (groin), infection (stoma), influenza, tooth abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ear residue, debris, or precipitate; ear sign or symptom (canal irritation); otitis externa</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, ENT infection (ear lobe), epistaxis, hemoptysis, nasal mucosa swelling, oropharyngeal pain, pneumonitis, productive cough, pulmonary infection, respiratory failure, upper respiratory tract infection (CMV)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration</p></div>
<div class="block coi drugH1Div" id="F51982008"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F52093532"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Development of antibodies may occur. In patients who experience a persistent decrease in preinjection levels of plasma adenosine deaminase (ADA) to &lt;15 mmol/hour/L and have had other causes ruled out (eg, noncompliance), antibody formation should be considered and a specific assay for antibody ADA should be performed. Dosage adjustments may be required in patients developing antibodies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune deficiency: Immune deficient patients are at increased risk of infection; maintain adequate precautions until improvement in immune function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Use with caution in patients with thrombocytopenia due to risk of injection site bleeding; avoid use in patients with severe thrombocytopenia.</p></div>
<div class="block foc drugH1Div" id="F52120397"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revcovi: Elapegademase-lvlr 2.4 mg/1.5 mL (1.5 mL)</p></div>
<div class="block geq drugH1Div" id="F52120395"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52184943"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Revcovi Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.4 mg/1.5 mL (per mL): $10,202.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614689"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: For IM administration only; do not administer IV or SubQ; remove vial from refrigerator and allow to reach room temperature for 30 minutes; using polypropylene syringe and a ≥25-gauge needle withdraw dose from vial; prior to administration, change needle to a gauge and length appropriate for the patient's age and anatomy; administer immediately and without further dilution; discard of any unused medication.</p></div>
<div class="block adm drugH1Div" id="F52093544"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IM: Administer intramuscularly; do not administer IV or SubQ. Do not dilute or mix with other medications prior to administration. Administer immediately after syringe preparation with an appropriate needle (size and gauge) for IM administration for the patient. Avoid administration near an artery or nerve. Periodically alternate injection site.</p></div>
<div class="block sts drugH1Div" id="F52093534"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Refrigerate at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light; do not freeze or shake. Do not use if previously frozen.</p></div>
<div class="block usep drugH1Div" id="F53571510"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F52013297"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F52013294"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F52093530"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">If treatment with elapegademase is needed during pregnancy, close monitoring is recommended.</p></div>
<div class="block mopp drugH1Div" id="F53571509"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline: Trough plasma adenosine deaminase (ADA) activity and trough erythrocyte deoxyadenosine nucleotides (dAXP) levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Following treatment initiation: Varies based on previous therapies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pegademase bovine (Adagen)-naive:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Plasma ADA activity (trough): Every 2 weeks during first 8 to 12 weeks of treatment, then every 3 to 6 months thereafter; perform testing for antibodies to elapegademase if persistent decrease in levels below 15 mmol/hour/L occurs. Monitor immune function and clinical status closely and take precautions to minimize infection if a persistent decrease in ADA activity occurs.</p>
<p style="text-indent:-2em;margin-left:6em;">Erythrocyte dAXP levels (trough): Two months after initiation and then at least twice annually.</p>
<p style="text-indent:-2em;margin-left:6em;">Total and subset lymphocytes (immune function): Every 4 to 8 weeks for up to a year after initiation and then every 3 to 6 months thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients converted from pegademase bovine (Adagen) to elapegademase (Revcovi):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Plasma ADA activity (trough): Every 4 weeks during first 8 to 12 weeks of treatment, then every 3 to 6 months thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">Erythrocyte dAXP concentrations (trough): Two months after initiation and then at least twice annually.</p>
<p style="text-indent:-2em;margin-left:6em;">Total and subset lymphocytes (immune function): Every 3 to 6 months.</p></div>
<div class="block rerp drugH1Div" id="F53570687"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Target concentrations:</p>
<p style="text-indent:-2em;margin-left:4em;">Plasma ADA activity: Trough: ≥30 mmol/hour/L.</p>
<p style="text-indent:-2em;margin-left:4em;">Erythrocyte dAXP concentration: Trough: &lt;0.02 mmol/L.</p></div>
<div class="block pha drugH1Div" id="F52093536"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Adenosine deaminase is an enzyme that catalyzes the deamination of both adenosine and deoxyadenosine. Hereditary lack of adenosine deaminase activity results in severe immunodeficiency disease, an often fatal disorder. Elapegademase is an exogenous source of adenosine deaminase enzyme that reduces levels of toxic adenosine and deoxyadenosine and increases lymphocytes.</p></div>
<div class="block phk drugH1Div" id="F52093537"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Time to peak: 27.2 to 72 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53745642"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Revcovi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Revcovi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Revcovi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Revcovi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Revcovi.1">
<a name="Revcovi.1"></a>Revcovi (elapegademase-lvlr) [prescribing information]. Cary, NC: Chiesi USA Inc; August 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119619 Version 51.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
